Revenue
2022
2023
2024
2025
PepGen Inc. (PEPG)
Price$3.11Cached quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | N/A |
| Research & development | $71.0M | $76.5M | $68.1M | $54.1M | $19.0M |
| Operating expenses | $93.6M | $97.7M | $84.8M | $68.3M | $27.1M |
| Operating income | −$93.6M | −$97.7M | −$84.8M | −$68.3M | −$27.1M |
| EBITDA | −$92.2M | −$96.2M | −$83.6M | −$67.8M | −$26.9M |
| Net income | −$89.7M | −$90.0M | −$78.6M | −$69.1M | −$27.3M |
| Basic EPSper basic share | -$2.12 | -$2.85 | -$3.30 | -$4.42 | -$30.27 |
| Diluted EPSper diluted share | -$2.12 | -$2.85 | -$3.30 | -$4.42 | -$30.27 |
Owners
Reported shareholders
≈28.97%of listed shares
RA CAPITAL MANAGEMENT, L.P.20.06M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
RA CAPITAL MANAGEMENT, L.P. | ≈28.97%20.06M shares |
Oxford Science Enterprises plc | ≈7.15%4.96M shares |
Commodore Capital LP | ≈6.46%4.48M shares |
VIKING GLOBAL INVESTORS LP | ≈5.03%3.48M shares |
Laurion Capital Management LP | ≈3.97%2.75M shares |
ADAR1 Capital Management, LLC | ≈3.74%2.59M shares |
Vivo Capital, LLC | ≈3.36%2.33M shares |
VANGUARD CAPITAL MANAGEMENT LLC | ≈2.80%1.94M shares |
MILLENNIUM MANAGEMENT LLC | ≈2.58%1.79M shares |
RENAISSANCE TECHNOLOGIES LLC | ≈2.19%1.52M shares |
BlackRock, Inc. | ≈1.88%1.3M shares |
MARSHALL WACE, LLP | ≈1.25%866.99K shares |
GSA CAPITAL PARTNERS LLP | ≈1.23%852.85K shares |
CITADEL ADVISORS LLC | ≈0.95%658.38K shares |
AWM Investment Company, Inc. | ≈0.87%600K shares |
MONIMUS CAPITAL MANAGEMENT, LP | ≈0.85%587.69K shares |
Squarepoint Ops LLC | ≈0.76%529.08K shares |
GEODE CAPITAL MANAGEMENT, LLC | ≈0.76%523.47K shares |
Creek Drive Management Group LLC | ≈0.65%450K shares |
Ikarian Capital, LLC | ≈0.65%447.17K shares |
Percentages use 69.26M shares of this listed class outstanding on Aug 2, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Oct 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 21, 2026Form 4 | Kasraian KasraChief Technical Officer | SellCommon Stock | 1.2K | $1.41 | $1.7K | 50.1K |
| Mar 4, 2026Form 4 | STRECK PAULEVP, Head of R&D | SellCommon Stock | 47 | $6.29 | $295.63 | 76.2K |
| Mar 4, 2026Form 4 | STRECK PAULEVP, Head of R&D | SellCommon Stock | 1.8K | $6.23 | $11.4K | 76.3K |
| Mar 4, 2026Form 4 | Donnelly NoelChief Financial Officer | SellCommon Stock | 52 | $6.33 | $329.16 | 111.6K |
| Mar 4, 2026Form 4 | Donnelly NoelChief Financial Officer | SellCommon Stock | 2.0K | $6.23 | $12.7K | 111.7K |
Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...
